Month: January 2013

January 8, 2013
Baxter to Initiate Late-Stage Trial of Longer Acting Advate

Baxter in the US has submitted an Investigational New Drug (IND) application for its investigational haemophilia A treatment BAX 855 with the US Food and Drug Administration, following positive results from a Phase I trial. BAX 855 is a full-length longer-acting recombinant factor VIII (rFVIII) developed to increase the half-life of Advate through PEGylation technology. …

Read article